Reshma Rangwala
About
Reshma Rangwala is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology.
According to data from OpenAlex, Reshma Rangwala has authored 41 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology. Recurrent topics in Reshma Rangwala's work include Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Treatments and Mutations (14 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Reshma Rangwala is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Treatments and Mutations (14 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Reshma Rangwala collaborates with scholars based in United States, Spain and Australia. Reshma Rangwala's co-authors include Rina Hui, Gregory M. Lubiniecki, Julie R. Brahmer, Mary O’Brien, Maya Gottfried, Delvys Rodríguez‐Abreu, Tibor Csőszi, Sinéad Cuffe, Ali Tafreshi and Suman Rao and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
Reshma Rangwala
40 papers receiving 9.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reshma Rangwala United States | 18 | 7.0k | 4.4k | 1.8k | 1.4k | 1.2k | 41 | 9.2k | ||
| Tibor Csőszi United States | 22 | 9.1k 1.3× | 5.8k 1.3× | 1.9k 1.1× | 1.3k 0.9× | 1.3k 1.1× | 82 | 10.7k | ||
| Michael Smylie Canada | 30 | 7.2k 1.0× | 4.4k 1.0× | 1.6k 0.9× | 2.4k 1.7× | 1.0k 0.9× | 92 | 9.1k | ||
| Andrea Fülöp Hungary | 9 | 7.9k 1.1× | 5.3k 1.2× | 1.8k 1.0× | 898 0.6× | 1.2k 1.0× | 14 | 9.2k | ||
| Suman Rao United States | 10 | 7.9k 1.1× | 5.4k 1.2× | 1.8k 1.0× | 895 0.6× | 1.2k 1.0× | 21 | 9.3k | ||
| Hossein Borghaei United States | 43 | 7.2k 1.0× | 4.6k 1.0× | 1.9k 1.0× | 1.4k 0.9× | 1.0k 0.9× | 258 | 9.0k | ||
| Yue Shentu United States | 15 | 10.7k 1.5× | 7.0k 1.6× | 2.5k 1.4× | 1.3k 0.9× | 1.5k 1.3× | 34 | 12.6k | ||
| Jamie E. Chaft United States | 43 | 7.0k 1.0× | 6.4k 1.5× | 1.0k 0.5× | 1.9k 1.3× | 1.5k 1.3× | 175 | 10.2k | ||
| Melanie A. Leiby United States | 6 | 6.1k 0.9× | 3.9k 0.9× | 1.5k 0.8× | 795 0.6× | 930 0.8× | 7 | 7.2k | ||
| Marcin Kowanetz United States | 45 | 9.3k 1.3× | 5.7k 1.3× | 2.6k 1.4× | 2.9k 2.0× | 1.8k 1.5× | 109 | 12.3k | ||
| Melissa L. Johnson United States | 42 | 5.0k 0.7× | 3.4k 0.8× | 1.2k 0.6× | 2.3k 1.6× | 1.1k 1.0× | 359 | 7.1k |
Countries citing papers authored by Reshma Rangwala
Since
Specialization
Citations
This map shows the geographic impact of Reshma Rangwala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reshma Rangwala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reshma Rangwala more than expected).
Fields of papers citing papers by Reshma Rangwala
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Reshma Rangwala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reshma Rangwala. The network helps show where Reshma Rangwala may publish in the future.
Co-authorship network of co-authors of Reshma Rangwala
This figure shows the co-authorship network connecting the top 25 collaborators of Reshma Rangwala. A scholar is included among the top collaborators of Reshma Rangwala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reshma Rangwala. Reshma Rangwala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hinchcliff, Emily, Elisabeth Gardiner, Reshma Rangwala, et al.. (2024). Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience. 27(5). 109801–109801.
2.
Fuh, Katherine C., Michael A. Bookman, Joyce F. Liu, et al.. (2021). Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecologic Oncology. 163(2). 254–261.
3.
Coleman, Robert L., Domenica Lorusso, Christine Gennigens, et al.. (2020). LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study. Annals of Oncology. 31. S1162–S1163.
4.
Hong, David S., Hendrik‐Tobias Arkenau, Johann S. de Bono, et al.. (2019). Tisotumab vedotin (TV) in patients with previously treated recurrent or metastatic cervical cancer: Updated safety and efficacy results from the full cervical cohort of the phase II innova TV 201 study (NCT02001623). Gynecologic Oncology. 154. 11–12.
5.
Satouchi, Miyako, Katsuyuki Hotta, Kaname Nosaki, et al.. (2017). Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC. Annals of Oncology. 28. ix73–ix73.
6.
Frenel, Jean‐Sébastien, Christophe Le Tourneau, Bert H. O’Neil, et al.. (2017). Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology. 35(36). 4035–4041.
7.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. Journal of Thoracic Oncology. 12(1). S8–S9.
8.
Garon, Edward B., Martin Reck, Delvys Rodríguez‐Abreu, et al.. (2017). P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1290–S1291.
9.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. The Lancet Oncology. 18(12). 1600–1609.
10.
Hui, Rina, Edward B. Garon, Natasha B. Leighl, et al.. (2017). Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Annals of Oncology. 28(4). 874–881.
11.
Herzog, Thomas J., et al.. (2016). Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer. International Journal of Gynecological Cancer. 26(9). 1580–1585.
12.
Lopes, Gilberto, Yi‐Long Wu, Jin Zhang, et al.. (2016). P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894). Journal of Thoracic Oncology. 11(10). S244–S245.
13.
Mok, Tony, Yi‐Long Wu, J. Zhang, et al.. (2016). 195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042. Journal of Thoracic Oncology. 11(4). S142–S142.
14.
Reck, Martin, Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2016). KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. Annals of Oncology. 27. vi578–vi578.
15.
Aggarwal, Charu, Delvys Rodríguez‐Abreu, Enriqueta Felip, et al.. (2016). Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024. Annals of Oncology. 27. vi363–vi363.
16.
Reck, Martin, Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 375(19). 1823–1833.
17.
Rangwala, Reshma, Robert D. Leone, Yunyoung C Chang, et al.. (2014). Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 10(8). 1369–1379.
18.
Vogl, Dan T., Edward A. Stadtmauer, Daniel F. Heitjan, et al.. (2014). Combined autophagy and proteasome inhibition. Autophagy. 10(8). 1380–1390.
19.
Barton, Lance F., Miguel Cruz, Reshma Rangwala, George S. Deepe, & John J. Monaco. (2002). Regulation of Immunoproteasome Subunit Expression In Vivo Following Pathogenic Fungal Infection. The Journal of Immunology. 169(6). 3046–3052.
20.
Wobus, Manja, Reshma Rangwala, Robert F. Hennigan, et al.. (2002). CD44 Associates With EGFR and erbB2 in Metastasizing Mammary Carcinoma Cells. Applied immunohistochemistry & molecular morphology. 10(1). 34–39.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tibor Csőszi Breakdown of academic impact, for papers by Michael Smylie Breakdown of academic impact, for papers by Andrea Fülöp Breakdown of academic impact, for papers by Suman Rao Breakdown of academic impact, for papers by Hossein Borghaei Breakdown of academic impact, for papers by Yue Shentu Breakdown of academic impact, for papers by Jamie E. Chaft Breakdown of academic impact, for papers by Melanie A. Leiby Breakdown of academic impact, for papers by Marcin Kowanetz Breakdown of academic impact, for papers by Melissa L. Johnson